Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Trading Update

7 Jan 2016 07:00

RNS Number : 0800L
Persimmon PLC
07 January 2016
 

 

TRADING UPDATE - 7 JANUARY 2016

 

 

Persimmon plc announces the following update ahead of its Final Results for the year ended 31 December 2015, which will be released on 23 February 2016.

 

2015 has been another year of strong growth for the Group, with legal completions increasing by 8% to 14,572 new homes (2014: 13,509). Further improvements to our build programmes supported the delivery of our strong carried forward sales at the mid-year stage, together with healthy sales taken through the autumn season. Our second half volumes of 7,717 legal completions were 13% stronger than the first half (H1: 6,855). The two new businesses opened during 2015 have made a solid start to trading, with Central delivering 160 new homes and Teesside 310 new homes during the year.

 

Revenues for 2015 of £2.9bn were 13% higher than the prior year (2014: £2.6bn), the Group's average selling price having increased by 4.5% to c. £199,100 (2014: £190,533).

 

The value of our forward sales at 31 December 2015 of c. £1,100m is 13% ahead of the prior year (2014: £973m). This provides a strong platform for the Group to continue to execute its long term strategy, which includes growing the business to take advantage of sustainable market opportunities. A further two new businesses based at Launceston in Cornwall and Perth in Scotland commenced trading on 4 January 2016 and will support this disciplined growth.

 

During 2015 we opened over 250 new development sites across the UK. The improved land recoveries on legal completions from these new sites, and strong control over costs, will result in a further increase in operating margins for the second half of the year as reported in November's trading update. The Group's expansion in output, together with improved operating profitability, will produce substantial growth in pre-tax profits and excellent cash generation for the year ended 31 December 2015. The Group's liquidity remains strong.

 

The Group has continued to identify compelling reinvestment opportunities in the land market which will deliver strong returns and cashflows over future years. We acquired c. 20,500 plots of new land over 123 sites with good deferred terms during the year. The consistent application of the requirements of the National Planning Policy Framework is supporting improvements in land release for development and the additional initiatives recently announced in the Autumn Statement should help further. The Group has an exciting pipeline of opportunities emerging from its strategic land portfolio and we remain well placed to realise our disciplined growth plans as part of the execution of our long term strategy.

 

The Group held cash balances of c. £570m at 31 December 2015 (2014: £378m).

 

We will give a further update on our assessment of the housing market over the early weeks of 2016 when we announce our results for the year ended 31 December 2015 on Tuesday 23 February 2016.

 

Please Note

There will be a call for analysts at 9.00 a.m. GMT today. Please use the dial-in details below:

 

Telephone number :

+44(0)20 3427 1903

Conference code :

Persimmon

 

An audiocast of the call will be available on www.corporate.persimmonhomes.com 

 

For further information please contact:

 

Jeff Fairburn, Group Chief Executive

Simon Rigby

Mike Killoran, Group Finance Director

Kevin Smith

Persimmon plc

Citigate Dewe Rogerson

Tel: +44 (0) 1904 642199

Tel: +44 (0) 20 7638 9571

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTMMGGMRVFGVZM
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.